A major criticism that should be made to all studies on predictive markers of clinical response to anti-EGFR agents in MCRC, including ours, is that the clinical response is evaluated on the metastatic disease whereas the presence of the molecular marker is assessed from the primary tumour. Here, EGFR is linked to metastatic neoplasm.